We approach a globalized world through the development of a business model with the capacity to respond to the needs of distinct pharmaceutical organizations in the region, and potentialize business models expressed through partnerships and alliances.

These partnerships have allowed us to expand Stein’s product portfolio, and to position ourselves as a representative and interlocutor in a market with different types of regulations and sociocultural conditions.

We develop innovation within a framework of utter respect for intellectual property. Each of our product development or business models are subject to rigorous scrutiny by our own legal and patent office. We continue to reassure our partner’s trust by conducting business in complete compliance with intellectual property agreements enforced in each country.

Our company manages a portfolio of more than 200 products ranging from painkillers to oncology treatments. Our current pipeline has over 90 products to be launched on the market in the next five years.